TLR9 agonists have been investigated for their capacity to enhance vaccine efficacy and treat viral infections such as hepatitis B virus (HBV) and hepatitis C virus (HCV) infections, as well as emerging viruses such as SARS-CoV-2. The gene discussed is TLR9; the disease is infection.